Table 2.
Study | Patients (stage) | Marker | Mean nodes examined | % pN0 (mol+) patients | Follow-up | Outcome | Recurrence rate | Clinical relevance |
Hayashi et al20 | 71 (1, 2) | MASA; K-ras, p53 | 14.5* | 52.1%* | 60 months | Recurrence within 5 years: mol−: 0%; mol+: 73%* | 41%* | P < 0.0001 |
Rosenberg et al21 | 85 (1, 2) | CK-20 | 2 (underwent RT-PCR) | 52% | 86 months (median) | OS: mol−: 94.7%; mol+: 77.9% | 21% | P < 0.009 |
Noura et al17 | 64 (2) | CEA | 5.5 | 29.7% | 79.5 months (mean) | DFS: mol−: 88.4%; mol+: 61.4% | 19%* | P = 0.027 |
Liefers et al19 | 26 (2) | CEA | 7.4* | 54% | 60 months | DSS: mol−: 91%; mol+: 50% | 31%* | P = 0.03 |
Merrie et al18 | 141 (1, 2) | CK-20 | 15.3* | 34% | 42 months (median) | OS: mol−: ∼85%; mol+: ∼70% | NA | P < 0.135 |
OS and # nodes: 0 mol+: ∼85%; 1 to 3 mol+: ∼75%; 4 mol+: ∼45% | NA | P < 0.0052 | ||||||
Bustin et al22 | 32 (1, 2) | GCC; CK20; CEA | 7.2† | NA | 47.3* months (median) | No association between mRNA expression levels and recurrence in pN0(mol+) patients | NA | NS (no P value) |
NA, not available; NS, not significant.
Figures are calculated or estimated based on data and tables found in the text.
Bustin and colleagues22 included 10 stage 3 patients in their study. This figure is calculated including all LNs from stage 1 to 3 patients.